Please enter exact key words
A Specific Antibody Against LGR5

for the Treatment of Solid Tumors

Home / Available Projects / A Specific Antibody Against LGR5
Drug Name GPCR-targeted Project 006

A monoclonal antibody that selectively binds to Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) is being developed to inhibit growth of cancer stem cells for the treatment of cancers. LGR5 is a protein that is normally expressed on intestinal stem cells, but is over-expressed on tumor-initiating stem cells in most cancers, including colon, breast, liver, lung, pancreatic, ovarian cancers, and other solid tumors. Cancer stem cells are often resistant to chemotherapy or other conventional forms of cancer therapy, and high expression of LGR5 in colon cancer has been associated with tumor recurrence and poor prognosis.

Target Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5)
Drug Modality Monoclonal antibody
Indication Colorectal cancer; Solid tumors
Product Category Biologic
Mechanism of Action LGR5 protein inhibitors
Status Preclinical
Patent Granted

More Detail Available Upon Request

We look forward to hearing from you.

Our customer service representatives are available 24 hours a day, from Monday to Sunday Online Inquiry

Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen Inc.